BIO-TECHNE INTEGRATES ITS MAURICE SYSTEM WITH THE THERMO SCIENTIFIC CHROMELEON CHROMATOGRAPHY DATA SYSTEM


Werte in diesem Artikel
Aktien

61.74 EUR -0.78 EUR -1.25 %

MINNEAPOLIS, Sept. 26, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to launch the new Maurice Chromeleon Driver Kit, which enables control of its Maurice™ instrument with the Thermo Scientific™ Chromeleon™ Chromatography Data System (CDS). In addition to Compass for iCE, and Waters™ Empower® CDS, scientists now can use Chromeleon CDS to analyze protein charge and size data generated from the Maurice system. This exciting development adds to the broad analytical capabilities on the Maurice system to provide a streamlined data analysis and management workflow.

Chromeleon CDS has become a preferred choice for laboratories and industries that rely on chromatography for quality control, research, and development. Its ability to enhance productivity, ensure data integrity, and facilitate compliance with regulatory requirements has solidified its status as a trusted chromatography data system. Meanwhile, the Maurice instrument has garnered widespread recognition for its exceptional performance and versatility in protein analysis. Maurice's ability to provide critical insights into charge heterogeneity, size, and impurity profiles of biotherapeutic drugs is rapidly making the system an indispensable analytical tool across labs. Now, by joining forces, the Maurice system and Chromeleon CDS will set new standards of efficiency and productivity in the laboratory. This integration enhances the capabilities of both technologies and simplifies the entire analytical workflow for researchers, particularly in labs where Chromeleon CDS is the data management system of choice. Scientists can now effortlessly interrogate capillary electrophoresis (CE) data with other chromatographic techniques, enabling a more holistic understanding of their samples.

"We are thrilled to introduce the integration of our Maurice CE instrument with Chromeleon CDS," said Will Geist, President of Bio-Techne's Protein Sciences segment. "This partnership furthers our commitment to advancing analytical technologies, simplifying workflows, and empowering scientists to achieve their research goals more efficiently."

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations
david.clair@bio-techne.com
612-656-4416

Bio-Techne

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-integrates-its-maurice-system-with-the-thermo-scientific-chromeleon-chromatography-data-system-301938301.html

SOURCE Bio-Techne Corporation

Aktuelle Bio-Techne Aktie News

Werbung

Bio-Techne Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Bio-Techne nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
DatumRatingAnalyst
31.10.18 Bio-Techne Hold Craig Hallum
18.01.17 Bio-Techne Buy Deutsche Bank AG
21.01.15 Bio-Techne Outperform Robert W. Baird & Co. Incorporated

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.